Adenocarcinoma News and Research

RSS

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

New Genomic Data Confirms a Single Pathway for Esophageal Adenocarcinoma

Scientists have found the strongest evidence to date that a condition known as Barrett's esophagus is the starting point for all cases of esophageal adenocarcinoma – the most common type of esophageal cancer in the developed world – even when telltale signs of this pre-cancerous stage are no longer visible.

16 Apr 2026

Study Maps Cellular Pathways Essential for Metaplasia and Precancerous Lesions in the Pancreas

Pancreatic ductal adenocarcinoma is the most common type of pancreatic cancer and has a low five-year survival rate.

6 Apr 2026

Mice Study Reveals Cholecystokinin as Key Driver of Obesity-Related Pancreatic Cancer

Obesity increases the body's need for insulin, forcing cells in the pancreas known as beta cells to ramp up insulin production to maintain blood sugar levels.

22 Mar 2026

How SARS-CoV-2 Hijacks Host tRNA Chemistry to Sustain Infection

Findings reveal coronaviruses exploit stress-linked tRNA modifications, enhancing translation efficiency and offering insights for antiviral drug development.

11 Mar 2026

New Tunable Device Enables Precise Size-Based Sorting of Cancer Cells

Poly(N-isopropylacrylamide) (PNIPAM) hydrogel undergoes significant but precise changes in size between 20 and 40 °C, making it an excellent candidate for use in variable-size deterministic lateral displacement (DLD) array devices.

8 Dec 2025

Senescent Fibroblasts in the Tumor Niche Rewire Lung Cancer Metabolism and Plasticity

Senescent fibroblasts are aging cells that no longer divide and protect against tumor development. Yet two decades have gone by since cell biologist Judith Campisi, PhD, paradoxically demonstrated that these same cells can promote cancer growth in a laboratory setting.

5 Dec 2025

Ferroptosis Suppression Identified as a Key Driver of Lung Cancer Growth

NYU Langone Health researchers found that a type of cell death caused by a buildup of highly reactive molecules suppresses lung tumor growth.

6 Nov 2025

EZH2 Inhibition Restores Order in Cancer Cell Division and Reduces Metastasis

Triple negative breast cancer (TNBC) is one of the most aggressive and hardest forms of breast cancer to treat, but a new study led by Weill Cornell Medicine suggests a surprising way to stop it from spreading.

6 Oct 2025

Tackling KRAS Mutations Unlocks New Hope for Pancreatic Cancer Patients

Accounting for nearly 90% of all pancreatic cancers, pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of just 13%. Late-stage diagnosis, limited surgical options, and toxic chemotherapy regimens contribute to its poor outcomes.

2 Sep 2025

CD276 Antibody Strategy Offers Hope For Immune-Resistant Lung Tumors

The study highlights 8H8_SDIE's role in activating NK cells against NSCLC, offering a new strategy for patients resistant to conventional immunotherapies.

6 Aug 2025

Exercise Boosts Immune Response in Cancer Through Bacterial Metabolites

A new study from the University of Pittsburgh shows for the first time how exercise improves cancer outcomes and enhances response to immunotherapy in mice by reshaping the gut microbiome.

10 Jul 2025

Study Identifies SMARCB1 and MEOX2 Genes as Growth Regulators of Lung Cancers

A Cancer Gene Therapy study reveals that MEOX2 promotes lung cancer progression while SMARCB1 acts as a tumor suppressor, influencing EGFR expression and response to tyrosine kinase inhibitors.

30 May 2025

Mutation Profiling Reveals Therapeutic Targets in Lung Squamous Cell Carcinoma

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation sequencing (NGS), the disease is challenging to treat due to the limited number of detectable mutations for targeted drug therapy.

27 May 2025

Tumor Recurrence Prediction from Multi-Omics Information by Deep Learning

MULGONET combines deep learning and multi-omics analysis to predict tumor recurrence, addressing interpretability and enhancing cancer prognosis understanding.

16 Apr 2025

Tumour-on-Chip Model Supports Preclinical Drug Development on Pancreatic Cancer

The biotech company Dynamic42, a specialist in organ-on-chip technology, has made a significant advance in pancreatic cancer drug research in collaboration with the research team of Prof. Dr. Nicole Teusch at the Institute of Pharmaceutical Biology and Biotechnology at Heinrich Heine University Düsseldorf.

7 Mar 2025